Galectin Therapeutics (GALT) Gains from Sales and Divestitures (2010 - 2025)
Galectin Therapeutics' quarterly Gains from Sales and Divestitures came in at $334000.0 in Q4 2025, up 902.01% quarter-over-quarter from $33333.0 in Q4 2012.
Galectin Therapeutics has reported Gains from Sales and Divestitures for 4 years, with the latest figure at $334000.0 in Q4 2025.
- For the quarter ending Q4 2025, Gains from Sales and Divestitures changed N/A year-over-year to $334000.0; the trailing twelve-month figure through Dec 2025 stood at $334000.0 (changed N/A YoY), and the FY2025 full-year result was $334000.0, changed N/A from the prior year.
- Gains from Sales and Divestitures for Q4 2025 stood at $334000.0, up from $33333.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $334000.0 in Q4 2025, with the low at $334000.0 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 334,000.00 |
| Dec 31, 2025 | 334,000.00 |
| Dec 31, 2012 | 33,333.00 |
| Dec 31, 2012 | 33,333.00 |
| Dec 31, 2011 | 7,500.00 |
| Dec 31, 2011 | 7,500.00 |
| Jun 30, 2011 | 45,000.00 |
| Jun 30, 2011 | 45,000.00 |
| Dec 31, 2010 | 8,334.00 |
| Dec 31, 2010 | 8,334.00 |
| Jun 30, 2010 | 25,000.00 |
| Jun 30, 2010 | 25,000.00 |